News & Press Releases

The Bio Report: Designing Small-Molecule, Immuno-Oncology Drugs That Act Like Biologics

Doug Manion, CEO of Kleo, talks about the company’s platform technology, why he thinks it will produce safer and more effective immunotherapies, and the potential to use these compounds in conjunction with existing biologics to enhance their activity.

Print Friendly, PDF & Email

Upcoming Events:

October 2020
No event found!